Petri Bono
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Gastroenterology top 0.5%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 39
- Cancer Immunotherapy and Biomarkers 13
- HER2/EGFR in Cancer Research 8
-
- Renal cell carcinoma treatment 23
- Prostate Cancer Treatment and Research 7
- Co-authors
- Heikki Joensuu (40 shared papers)Pirkko‐Liisa Kellokumpu‐Lehtinen (16 shared papers)Vesa V Kataja (14 shared papers)Sirpa Jalkanen (12 shared papers)Kari K. Alitalo (4 shared papers)Marko Salmi (9 shared papers)Pipsa Saharinen (4 shared papers)Lauri Eklund (1 shared paper)
- Journals
- Annals of Oncology (19 papers)European Journal of Cancer (11 papers)Acta Oncologica (8 papers)Journal of Clinical Oncology (7 papers)The Lancet Oncology (6 papers)
- Partner nations
- FinlandUnited StatesUnited Kingdom
In The Last Decade
Petri Bono
127 papers receiving 15.2k citations
Petri Bono's Hit Papers
Peers
Comparison fields: 5 of 122
- Oncology 7.5k
- Gastroenterology 1.0k
- Cancer Research 2.2k
- Pulmonary and Respiratory Medicine 4.6k
- Immunology 2.1k
Countries citing papers authored by Petri Bono
This map shows the geographic impact of Petri Bono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petri Bono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petri Bono more than expected).
Fields of papers citing papers by Petri Bono
This network shows the impact of papers produced by Petri Bono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petri Bono. The network helps show where Petri Bono may publish in the future.
Co-authors
The 25 scholars most cited alongside Petri Bono, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 131 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer Hit paper breakdown → | 2006 | 1149 |
| 3 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Hit paper breakdown → | 2016 | 1067 |
| 4 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Hit paper breakdown → | 2014 | 1066 |
| 5 | One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor Hit paper breakdown → | 2012 | 779 |
| 6 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Hit paper breakdown → | 2016 | 569 |
| 7 | 2011 | 419 | |
| 8 | 2009 | 367 | |
| 9 | Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study Hit paper breakdown → | 2014 | 334 |
| 10 | 1998 | 266 | |
| 11 | 2006 | 257 | |
| 12 | 2019 | 198 | |
| 13 | 2005 | 187 | |
| 14 | 2015 | 172 | |
| 15 | 2014 | 168 | |
| 16 | 2004 | 157 | |
| 17 | 2001 | 134 | |
| 18 | 2017 | 134 | |
| 19 | 2011 | 130 | |
| 20 | 2013 | 127 |
About Petri Bono
Petri Bono is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 131 papers that have together received 15.5k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (13 papers), Angiogenesis and VEGF in Cancer (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (8 papers), Microbial metabolism and enzyme function (7 papers), Prostate Cancer Treatment and Research (7 papers) and Breast Cancer Treatment Studies (6 papers). The work is most often cited by research in Oncology (7.5k citations), Gastroenterology (1.0k citations), Cancer Research (2.2k citations), Pulmonary and Respiratory Medicine (4.6k citations) and Immunology (2.1k citations). Petri Bono has collaborated with scholars based in Finland, United States and United Kingdom. Frequent co-authors include Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Vesa V Kataja, Sirpa Jalkanen, Kari K. Alitalo, Marko Salmi, Pipsa Saharinen, Lauri Eklund, Sherene Loi and Debora Fumagalli. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Acta Oncologica, Journal of Clinical Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.